Eli Lilly is channeling profits from its obesity treatments into further acquisitions, according to CNBC's Investing Club. The move comes as the company continues to capitalize on the booming demand for weight-loss drugs, using that cash flow to expand its portfolio.
Separately, comments from Elon Musk were pulling shares of GE Vernova lower in afternoon trading. The remarks added pressure to the stock, which had been trading in the last hour of the session.
The updates were part of the Investing Club's Homestretch, a daily afternoon brief published just in time for the final hour of trading on August 31, 2026.
Obesity profits fund dealmaking
Lilly's decision to reinvest its obesity windfall into M&A underscores the scale of its success in that market. The company has not disclosed specific targets or terms, but the strategy signals an intent to build on its momentum through acquisitions.
Musk's remarks weigh on GE Vernova
GE Vernova's decline followed Elon Musk's comments, though the exact nature of those remarks was not detailed in the source. The stock's reaction highlights how quickly sentiment can shift in response to influential voices.
What to watch
Investors will be watching for further details on Lilly's M&A plans and whether GE Vernova can recover from the Musk-driven dip. The Homestretch update offers a snapshot, but the full impact of these developments may unfold in the coming sessions.